Close
FINDING CURES TOGETHER<sup>SM</sup>

Advances in Prostate Cancer Research

​Program 


Thursday, March 12


Friday, March 13

Speaker to be announced


Opening Reception
6-7:30 p.m.


Top of page


Friday, March 13

Continental Breakfast
7-8 a.m.


Plenary Session 1: Biological Drivers of Risk - Carcinogenesis and Early Prostate Cancer
8-10 a.m.

Title to be announced
Rosalind A. Eeles, Institute of Cancer Research, Sutton, United Kingdom

Title to be announced
Christopher A. Haiman, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California

Title to be announced
Veda N. Giri, Fox Chase Cancer Center, Philadelphia, Pennsylvania

2 short talks from proffered abstracts


Break
10-10:30 a.m.


Plenary Session 2: DNA Repair
10:30 a.m.-12:30 p.m.

Title to be announced
Karen E. Knudsen, Thomas Jefferson University Kimmel Cancer Center, Philadelphia, Pennsylvania 

Title to be announced
Robert G. Bristow, University of Manchester, Manchester, United Kingdom

Precision therapy with DNA-targeted drugs 
Yves G. Pommier, National Cancer Institute, Bethesda, Maryland

2 short talks from proffered abstracts


Free Time / Lunch on Own
12:30-2:30 p.m.


Plenary Session 3: Drivers of Tumor Evolution and Plasticity
2:30-4:30 p.m.

Prostate cancer therapeutics create new species and new targets
Peter S. Nelson, Fred Hutchinson Cancer Research Center, Seattle, Washington 

Title to be announced
Himisha Beltran, Dana-Farber Cancer Institute, Boston, Massachusetts

Title to be announced
Felix Y. Feng, University of California San Francisco, San Francisco, California 

2 short talks from proffered abstracts


Poster Session A / Reception
4:30-7 p.m.


Top of page


Saturday, March 14

Continental Breakfast
7-8 a.m.


Plenary Session 4: Advances in Detection and Diagnosis
8-10 a.m.

PSA: How a great marker turned into a public health fiasco (and how to turn it back)
Andrew Vickers, Memorial Sloan Kettering Cancer Center, New York, New York

Pathology A.I. to identify novel phenotype: Genotype associations in aggressive prostate cancer
Beatrice S. Knudsen, Cedars-Sinai Medical Center, New York, New York

Title to be announced
Nickolas Papadopoulos, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

Using deep learning to improve Gleason grading of prostate cancer specimens
Craig Mermel, Google Health, Palo Alto, California


Break
10-10:30 a.m.


Plenary Session 5: Hormone Receptor Signaling and Crosstalk
10:30 a.m.-12:30 p.m.

Landscape of AR gene rearrangements in prostate cancer
Scott M. Dehm, University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota 

Intense androgen deprivation therapy with prostatectomy for localized high-risk prostate cancer
Mary-Ellen Taplin, Dana-Farber Cancer Institute, Boston, Massachusetts

Androgen receptor switch in treatment resistance
Amina Zoubeidi, Vancouver Prostate Center, Vancouver, BC, Canada

2 short talks from proffered abstracts


Poster Session B / Lunch
12:30-3 p.m.


Plenary Session 6: Metabolism
3-5 p.m.

Steroid metabolism drivers of prostate cancer resistance to hormonal therapies
Nima Sharifi, The Cleveland Clinic Lerner Research Institute, Cleveland, Ohio

Title to be announced
Massimo Loda, Weill Cornell Medical College, New York, New York 

Therapeutic exploitation of nuclear receptors/nuclear receptor-regulated pathways in cancer
Donald P. McDonnell, Duke University Medical Center, Durham, North Carolina

2 short talks from proffered abstracts


Evening on Own
5 p.m.-




Sunday, March 15

Continental Breakfast
7-8 a.m.


Plenary Session 7: Tumor and Immune Microenvironment
8-10 a.m.

From the clinic to the lab: Investigating response and resistance mechanisms to immune checkpoint therapy
Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, Texas

Title to be announced
Charles G. Drake, Columbia University Medical Center, New York, New York

Tumor microenvironment: The immunotherapy detective's treasure trove
James L. Gulley, National Cancer Institute, Bethesda, Maryland

2 short talks from proffered abstracts


Break
10-10:30 a.m.


Plenary Session 8: Novel Targets
10:30 a.m.-12:30 p.m.

Next-generation therapeutics in the face of the changing landscape of prostate cancer biology
Marco M. Gottardis, Janssen R&D, Spring House, Pennsylvania

Title to be announced
Levi A. Garraway, Eli Lilly and Company, Indianapolis, Indiana

Optimizing precision care for patients with advanced prostate cancer: From patient identification to therapy
Scott A. Tomlins, University of Michigan Medical School, Ann Arbor, Michigan

2 short talks from proffered abstracts


Closing Keynote
12:30-1:30 p.m.

Title to be announced
Johann S. de Bono, Institute of Cancer Research, Sutton, United Kingdom


Closing Remarks
1:30 p.m.

Felix Y. Feng, University of California San Francisco, San Francisco, California
Karen E. Knudsen, Thomas Jefferson University Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania
Scott A. Tomlins, University of Michigan Medical School, Ann Arbor, Michigan